R-CHOP protocol: Clinical Trials

7 trials of R-CHOP protocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 unknown, 1 not yet recruiting. 7 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Active not recruiting 3, Unknown 3, Not yet recruiting 1
Phase 26Active not recruiting 3, Unknown 2, Not yet recruiting 1

Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University1222026-02-282026-02-10
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Phase 1 / Phase 2UnknownSun Yat-sen University542022-11-012023-12-14
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingIncyte Biosciences Japan GK722020-12-152026-10-21
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab5432020-11-032026-11-03
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab782020-08-202026-11-04
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases
Phase 1UnknownAcrotech Biopharma Inc.562020-08-152020-04-16
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14

Conditions studied

Lymphoma, Large B-Cell, Diffuse (5)  ·  Lymphoma, Follicular (2)  ·  Pyloric Stenosis, Hypertrophic (2)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Non-Hodgkin (1)

Sponsors

Genmab (2)  ·  Sun Yat-sen University (2)  ·  Acrotech Biopharma Inc. (1)  ·  Huiqiang Huang (1)  ·  Incyte Biosciences Japan GK (1)

Countries

China (3)  ·  Japan (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Wasim Khan, MD (1)

Results publications

PMID 39792928, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129

NIH funding

2023 (1)